Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
63 Type 1 Diabetes Trials near Miami, FL
Power is an online platform that helps thousands of Type 1 Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
DIAGNODE-3 study for recently diagnosed type I diabetes
Miami, FloridaThis trial tests if using Diamyd and Vitamin D can help young people and adults with Type 1 Diabetes. The goal is to help their bodies keep making insulin for longer. High dose vitamin D and omega 3 have shown promise in prolonging remission in Type 1 Diabetes.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 28
Sex:All
Key Eligibility Criteria
Disqualifiers:Pancreatic Disorders, Hepatic Disease, Others
Must Be Taking:Insulin
330 Participants Needed
Islet Transplantation for Type 1 Diabetes
Miami, FloridaThe intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Subject will remain flat on their back for 1 - 3 hours after islet infusion to maximize adhesion of the islets to the iris.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Glaucoma, HbA1c >10%, Hypertension, Others
Must Not Be Taking:Topical Steroids, Immune-modulatory Drugs
2 Participants Needed
HDV-Insulin Lispro for Type 1 Diabetes
Miami, FloridaThe goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 79
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Liver Abnormalities, Drug Abuse, Others
Must Be Taking:Insulin
230 Participants Needed
JAK Inhibitors for Type 1 Diabetes
Miami, FloridaThis trial is testing two medications, abrocitinib and ritlecitinib, which aim to reduce immune system activity. The study focuses on people who have been recently diagnosed with Stage 3 Type 1 Diabetes. These medications work by calming the immune system to prevent it from attacking insulin-producing cells in the pancreas.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35
Sex:All
Key Eligibility Criteria
Disqualifiers:Infections, Cancer, Heart Disease, Others
Must Not Be Taking:Immunosuppressants, Biologics, Steroids, Others
78 Participants Needed
Ladarixin for Type 1 Diabetes
Miami, FloridaThis trial is testing ladarixin, a medication that may help protect insulin-producing cells in the pancreas. It targets adolescents and adults who have been diagnosed with type 1 diabetes, especially those with severe cases. The goal is to see if ladarixin can slow down the progression of the disease and keep these cells working longer.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:14 - 45
Sex:All
140 Participants Needed
Low-Dose ATG for Type 1 Diabetes
Miami, FloridaA multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:6 - 34
Sex:All
101 Participants Needed
VX-264 for Type 1 Diabetes
Miami, FloridaThe purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Islet Transplant, Organ Transplant, Others
17 Participants Needed
CELZ-201 for Type 1 Diabetes
Miami, FloridaThis trial is testing CELZ-201, a new treatment for people who have just been diagnosed with Type 1 Diabetes. The treatment is given directly into the bloodstream to help control blood sugar levels.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 35
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Liver Disease, Hypertension, Others
Must Be Taking:Insulin
18 Participants Needed
VX-880 for Type 1 Diabetes
Miami, FloridaThis trial will test the safety and effectiveness of VX-880 infusion in people with Type 1 diabetes who have trouble sensing low blood sugar and experience severe low blood sugar episodes. The treatment aims to help manage their blood sugar levels better.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Prior Transplants, Cell Therapy, Others
52 Participants Needed
Frexalimab + Insulin for Type 1 Diabetes
Miami, FloridaThis trial is testing a new drug called frexalimab in young people with newly diagnosed Type 1 Diabetes. The goal is to see if it can help their bodies keep making insulin. The study will compare different doses of the drug to find the safest and most effective amount.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35
Sex:All
Key Eligibility Criteria
Disqualifiers:Infections, Autoimmune Diseases, Malignancy, Others
Must Be Taking:Insulin
192 Participants Needed
Myfortic for Type 1 Diabetes Islet Transplant Recipients
Miami, FloridaThis is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Hyperlipidemia, Obesity, Hypertension, Others
Must Be Taking:Immunosuppressive Medications
18 Participants Needed
Siplizumab for Type 1 Diabetes
Miami, FloridaThis is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites.
The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM.
The secondary objectives are to:
1. Assess the safety profile of siplizumab in recently diagnosed T1DM.
2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:8 - 45
Sex:All
120 Participants Needed
Rituximab + Abatacept for Type 1 Diabetes
Maimi, FloridaThis trial is testing whether a combination of two drugs, rituximab-pvvr followed by abatacept, can better preserve insulin production in people newly diagnosed with Type 1 Diabetes compared to rituximab-pvvr alone. Rituximab-pvvr works by reducing harmful immune cells, while abatacept helps calm the immune system. The goal is to see if this combination can improve insulin production and overall diabetes management.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:8 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Immune Deficiency, Chronic Infection, Others
Must Not Be Taking:Non-insulin Glycemic
74 Participants Needed
Finerenone for Chronic Kidney Disease in Type 1 Diabetes
Miami, FloridaThis trial is testing finerenone, a drug that helps protect kidneys and hearts, in people with chronic kidney disease and type 1 diabetes. The study aims to see how well finerenone works in slowing down kidney damage. Researchers will also monitor the safety of the drug by tracking any medical issues participants experience. Finerenone has been shown to delay the progression of chronic kidney disease and reduce cardiovascular events in patients with diabetic kidney disease, particularly type 2 diabetes.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
220 Participants Needed
Eversense CGM for Diabetes
Miami, FloridaThis study is evaluating whether a continuous glucose monitor may help people with diabetes better manage their blood sugar.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Critically Ill, Dialysis, Pregnant, Others
Must Not Be Taking:Dexamethasone
925 Participants Needed
Inhaled Insulin for Diabetes in Children
Hollywood, FloridaThis trial tests an inhalable insulin called Afrezza, combined with a long-acting insulin, in children and teenagers with diabetes. Afrezza helps lower blood sugar quickly after eating, and the long-acting insulin keeps it stable all day. The study aims to see if this combination is safe and effective.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 17
Sex:All
319 Participants Needed
BMF-219 for Type 1 Diabetes
North Miami Beach, FloridaThis trial tests BMF-219, an oral medication that blocks a protein called menin, in people with Type 1 Diabetes. The goal is to see if it can help their insulin-producing cells work better and improve how their bodies handle sugar and fats.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 70
Sex:All
190 Participants Needed
Tirzepatide vs Dulaglutide for Type 2 Diabetes
Hollywood, FloridaThe purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
13299 Participants Needed
MET097 for Diabesity
Hollywood, FloridaThis study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
125 Participants Needed
R-5280 (HAMS-AB) for Type 1 Diabetes
Plantation, FloridaEvaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:11 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 2 Diabetes, Pregnancy, Celiac, Others
Must Not Be Taking:Steroids, Immunosuppressants, Antibiotics, Others
39 Participants Needed
ZT-01 for Type 1 Diabetes
West Palm Beach, FloridaThis trial is testing a drug called ZT-01 to help adults with type 1 diabetes who have low blood sugar at night. ZT-01 increases a hormone that raises blood sugar levels. The study will see if ZT-01 reduces nighttime low blood sugar episodes and check its safety.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 2 Diabetes, Kidney Disease, Others
186 Participants Needed
CT-868 for Type 1 Diabetes
Port Charlotte, FloridaThis trial is testing a new treatment called CT-868 to see if it helps overweight and obese adults with Type 1 Diabetes control their blood sugar better. Participants will continue their regular insulin therapy and receive either CT-868 or another treatment. The goal is to find out if CT-868 can make blood sugar levels more stable.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
111 Participants Needed
Transdisciplinary Care for Type 1 Diabetes
Orlando, FloridaThe incidence of type 1 diabetes (T1D) is increasing globally with the most substantial increases occurring in the youngest age groups. A growing number of youths with T1D must therefore transition their healthcare from pediatric to adult T1D care settings as they approach young adulthood. This healthcare transition introduces many challenges because it coincides with a developmental period that is fraught with social, financial, residential, school/work and other changes/demands. Thus, it is not surprising that young adults (YA) with T1D are at risk for suboptimal glycemic levels, the development of diabetes-related complications, and psychosocial issues such as depression, anxiety, and disordered eating. Yet, few evidence-based interventions to assist YA with T1D with this complex healthcare transition exist.
In this study, we are testing the feasibility, acceptability, and initial efficacy of a novel transdisciplinary model of care (Transdisciplinary Care for Transition; TCT) in which a diabetes nurse educator, psychologist, and transition navigator (case manager) co-deliver transitional care. TCT addresses the psychological and systems barriers to transition and aims to improve outcomes via better assessment of YA needs and resources, better cross-discipline and YA-provider communication, and better collaboration with YA to resolve problems that cross pediatric and adult healthcare settings.
We will recruit 80 YA with T1D during their final visit in pediatric T1D specialty care to participate in a pilot randomized controlled trial during which we will randomize YA to a standard care control group (SCC) or to receive three TCT visits during the 6 months post discharge from pediatric T1D care. In SCC, participants will transition to adult T1D care as usual per their clinic's standard transition procedures.
All study procedures can be completed remotely. This includes enrollment, study evaluations, and TCT visits for those randomized to TCT. Thus, we are recruiting individuals from across the United States.
Aim 1: Examine the feasibility, acceptability, and fidelity of TCT in YA with T1D.
Aim 2: Examine the preliminary efficacy of TCT versus SCC on YA HbA1c, transition readiness and success, and continuity of care and explore for an effect on diabetes distress and acute care utilization.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:17 - 20
Sex:All
Key Eligibility Criteria
Disqualifiers:Developmental Disability, Chronic Illness, Others
80 Participants Needed
Single Session Intervention for Type 1 Diabetes
Orlando, FloridaThe goal of this clinical trial is to learn if implementing a single-session depression intervention for youth with type 1 diabetes (T1D) is feasible and acceptable to patients. can help improve mood and health outcomes. It will also learn about the initial efficacy of the intervention. The main questions it aims to answer are:
1. Is a single-session depression intervention for youth with T1D feasible to recruit and implement?
2. Is a single-session depression intervention for youth with T1D acceptable to patients (i.e., do they find it helpful)?
3. Does a single-session depression intervention for youth with T1D lead to improvements in low mood?
Researchers will compare a single-session depression intervention for youth with to a education control to see if a single-session depression intervention works to improve depressive symptoms.
Participants will:
* Participate in a single-session depression intervention
* Complete questionnaires and provide a sample for A1c at a baseline, 3-month, and 6-month visit
* Complete daily questionnaires once a day for two weeks before and after the single-session depression intervention
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:12 - 17
Sex:All
80 Participants Needed
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:2 - 6
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Hypoglycemia, Uncontrolled Diabetes, DKA, Others
Must Be Taking:Insulin
60 Participants Needed
Closed Loop Systems + Education for Type 1 Diabetes
Orlando, FloridaThe purpose of the CLEAR study is to determine the effect on counterregulatory responses (CRR) of intervening (by attempting to strictly avoid hypoglycemia) to improve awareness of hypoglycemic symptoms among adults with type 1 diabetes (T1D) who have impaired awareness of hypoglycemia (IAH). IAH affects 20-25% of adults with T1D, and rises with increasing duration of T1D.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
324 Participants Needed
Mindfulness Training for Type 1 Diabetes Anxiety
Tampa, FloridaThis trial tests a mobile app designed to help teens with Type 1 diabetes reduce anxiety through regular mindfulness exercises. The app aims to improve their mental health by teaching them to focus on the present moment and manage stress better.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 19
Sex:All
Key Eligibility Criteria
Disqualifiers:Chronic Condition, Others
40 Participants Needed
Hybrid Closed Loop System for Type 1 Diabetes
Tampa, FloridaThe purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:2 - 80
Sex:All
280 Participants Needed
MiniMed™ 780G System for Type 2 Diabetes
Tampa, FloridaThis trial is testing the MiniMed™ 780G system, which includes an insulin pump and sensors, in adults aged 18-80 with type 2 diabetes who need insulin. The device continuously checks blood sugar levels and automatically adjusts insulin delivery to keep blood sugar stable. The study will last several months and involve up to 575 participants across the United States. The MiniMed™ 780G system is an advanced hybrid closed-loop system that has been previously tested in various populations, including adolescents and adults with type 1 diabetes, showing improvements in blood sugar control.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
575 Participants Needed
Del-desiran for Myotonic Dystrophy
Tampa, FloridaA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:16 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Diabetes, Heart Failure, Others
Must Not Be Taking:Anti-myotonic Medications
150 Participants Needed
Page 1 of 3+
Frequently Asked Questions
How much do Type 1 Diabetes clinical trials in Miami, FL pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Type 1 Diabetes clinical trials in Miami, FL work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Type 1 Diabetes trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Type 1 Diabetes is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Type 1 Diabetes medical study in Miami, FL ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Type 1 Diabetes clinical trials in Miami, FL ?
Most recently, we added GNTI-122 for Type 1 Diabetes, SGLT2 Inhibitor for Type 1 Diabetes and Continuous Glucose Monitoring for Diabetes to the Power online platform.